SLC5A2 and hydrops fetalis: This effect was observed in patients both with and without type 2 DM.33 A meta-analysis of the DAPA-HF and EMPEROR-Reduced trials demonstrated that SGLT2 inhibitors improve renal outcomes, cardiovascular and all-cause mortality in HFrEF patients.34 SGLT2 inhibitors were not standard therapy for patients with type 2 DM and HFrEF at the time of our data collection.